Medicare weighs in on negotiating drug prices; Illumina moves forward to stay ahead of its rivals

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      STAT+: Medicare lays out the bureaucracy it will need to negotiate drug prices By Rachel Cohrs Adobe New documents obtained by STAT outline how Medicare is planning to build out its bureaucracy to handle its new power to negotiate drug prices. Read More STAT+: With rivals on its heels, Illumina launches a new line of high-end DNA sequencers By Jonathan Wosen Adobe Illumina's NovaSeq X Series can churn out up to 20,000 human genomes in a year, 2.5 times the max output of the company’s current machines. Read More Listen: A surprise success in Alzheimer's and how FDA history seeded modern controversy By Damian Garde and Allison DeAngelis and Adam Feuerstein Alzheimer's drug lecanemab succeeded in a pivotal clinical trial, and we explain the surprising development and its sweeping implications. Read More Sponsor content by Thermo Fisher Science is making it possible to remove the word 'serial' from crime Fred Harran, Public Safety Director for the Bensalem Township police department, is bringing a new sense of safety to the residents of his community thanks to advancements in DNA analysis technology. Read more. Juul exec slams FDA over its approach to regulating vaping By Nicholas Florko Seth Wenig/AP A Juul executive fiercely criticized the FDA approach toward regulating vaping companies during a tobacco industry conference Thursday. Read More Thursday, September 29, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser